Dyadic International, Fermbox Bio expand strategic collaboration

Dyadic Applied BioSolutions announced a significant expansion of its collaboration with Fermbox Bio. This expanded partnership broadens the range of products, platforms, and commercial opportunities the companies will jointly deliver to market. Building on their longstanding relationship, this agreement enables Fermbox Bio to manufacture and commercialize an expanding portfolio of Dyadic-developed proteins and enzymes using both the Dapibus and C1 expression systems. Dyadic will co-commercialize these products globally, strengthening its capacity to bring scalable, animal-free solutions to life science, food and nutrition, and bioindustrial sectors. The agreement also allows both parties to incorporate products developed on Fermbox Bio’s proprietary microbial platforms into the joint portfolio, creating a more diverse and competitive pipeline of fermentation-derived biomolecules. Key elements of the expanded collaboration include: Manufacture of multiple Dyadic-origin products by Fermbox Bio, enabling efficient production and market expansion of sustainable, animal-free proteins and enzymes. Dual-Sourcing flexibility, allowing both companies to supply production strains and finished products, produced via C1, Dapibus, or alternative microbial systems. Integration of Fermbox-developed products into the joint commercial portfolio, where mutually agreed. A jointly managed, continuously updated product pipeline, allowing the companies to add new commercial opportunities as markets and customer needs evolve.